Preoperative chemoradiotherapy with capecitabine and triweekly oxaliplatin versus capecitabine monotherapy for locally advanced rectal cancer: a propensity-score matched study

• Published in: BMC cancer 2022-07, Vol.22 (1), p.1-789, Article 789
• Main Authors: Li, Anchuan, Huang, Tingxuan, Zheng, Rong, Chi, Pan, Li, Zhihua, Wang, Xiaozhong, Xu, Benhua
• Format: Article
• Language: English
• Subjects: Adjuvant treatment; Antimitotic agents; Antineoplastic agents; Cancer; Cancer therapies; Capecitabine; Care and treatment; Chemoradiotherapy; Chemotherapy; Colorectal cancer; Complications; Diagnosis; Dosage and administration; Hospitals; Lymphatic system; Medical prognosis; Metastases; Metastasis; Oxaliplatin; Patients; Postoperative; Prevention; Radiation therapy; Rectal cancer; Rectum; Relapse; Risk factors; Surgeons; Surgery; Survival; Tomography; Toxicity
• ISSN: 1471-2407; 1471-2407
• DOI: 10.1186/s12885-022-09855-z

Background Distant metastasis has been the main failure pattern for locoregionally advanced rectal cancer (LARC) patients, and intensified neoadjuvant chemotherapy has become a popular research topic. The present study aimed to compare the survival outcomes, acute toxicities and surgical complications in LARC patients who received preoperative chemoradiotherapy with triweekly oxaliplatin and capecitabine (triweekly XELOX) or capecitabine. Methods: Between 2007 and 2017, patients with clinically staged II-III rectal cancer who were treated with preoperative chemoradiotherapy using either triweekly XELOX (oxaliplatin 130 mg/m.sup.2 plus capecitabine 825 mg/m.sup.2) or capecitabine were included. Variables potentially influencing chemotherapy treatment selection were used to generate propensity scores (PS). The association between chemotherapy regimens and survival endpoints, including distant metastasis-free survival (DMFS), overall survival (OS) and disease-free survival (DFS), were evaluated and adjusted with PS. The acute toxicities and surgical complications were also compared. Results A total of 810 patients were included in the analysis; 277 (34.2%) patients received triweekly XELOX, and 533 (65.8%) received capecitabine. The pathological complete response (pCR) rates were 20.2 and 19.9% (P = 0.912) for the groups treated with triweekly XELOX and capecitabine, respectively. The 5-year DMFS, OS and DFS with triweekly XELOX versus capecitabine were 75.6% vs. 77.6% (P = 0.555), 79.2% vs. 83.3% (P = 0.101), and 69.9% vs. 73.7% (P = 0.283), respectively. Triweekly XELOX was not associated with an increased risk of severe toxicity during chemoradiotherapy, but it increased the risk of postoperative complications compared to capecitabine. After PS adjustment, the differences between the two groups remained insignificant in pCR rate, survival outcomes, and acute toxicities, and the difference in surgical complications disappeared. Conclusions Triweekly XELOX or capecitabine concurrent with neoadjuvant radiotherapy leads to similar long-term survival outcomes, acute toxicities and surgical complications in LARC patients. Keywords: Rectal cancer, Oxaliplatin, Capecitabine, Chemoradiotherapy